Cantor Fitzgerald reiterated their underweight rating on shares of bluebird bio (NASDAQ:BLUE) in a research note issued to investors on Wednesday.
A number of other research analysts have also recently commented on BLUE. BidaskClub cut bluebird bio from a strong-buy rating to a buy rating in a research note on Tuesday, January 16th. Leerink Swann cut bluebird bio from an outperform rating to a market perform rating and lifted their price objective for the company from $162.00 to $194.00 in a research note on Thursday, January 25th. Canaccord Genuity reiterated a buy rating and set a $250.00 price objective on shares of bluebird bio in a research note on Thursday, February 1st. Sanford C. Bernstein reiterated a hold rating and set a $211.00 price objective (up previously from $153.00) on shares of bluebird bio in a research note on Thursday, February 22nd. Finally, BMO Capital Markets set a $222.00 price objective on bluebird bio and gave the company a buy rating in a research note on Thursday, February 22nd. Four equities research analysts have rated the stock with a sell rating, nine have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of Hold and an average price target of $195.80.
bluebird bio opened at $183.70 on Wednesday, according to MarketBeat Ratings. The company has a market capitalization of $9.49 billion, a PE ratio of -23.83 and a beta of 2.17. bluebird bio has a 52 week low of $74.45 and a 52 week high of $236.17.
bluebird bio (NASDAQ:BLUE) last released its earnings results on Monday, May 7th. The biotechnology company reported ($2.31) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.01) by ($0.30). The firm had revenue of $15.96 million during the quarter, compared to analysts’ expectations of $5.85 million. bluebird bio had a negative net margin of 857.55% and a negative return on equity of 27.61%. The company’s revenue for the quarter was up 133.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.68) EPS. analysts expect that bluebird bio will post -9.33 earnings per share for the current year.
In other bluebird bio news, insider David Davidson sold 13,000 shares of bluebird bio stock in a transaction on Wednesday, May 2nd. The stock was sold at an average price of $177.52, for a total value of $2,307,760.00. Following the completion of the sale, the insider now owns 37,905 shares of the company’s stock, valued at approximately $6,728,895.60. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Mark Vachon sold 6,000 shares of bluebird bio stock in a transaction on Thursday, March 15th. The stock was sold at an average price of $214.38, for a total value of $1,286,280.00. Following the completion of the sale, the director now directly owns 7,000 shares of the company’s stock, valued at approximately $1,500,660. The disclosure for this sale can be found here. In the last three months, insiders sold 46,250 shares of company stock valued at $8,269,990. Corporate insiders own 3.90% of the company’s stock.
Institutional investors have recently bought and sold shares of the business. Meeder Asset Management Inc. increased its holdings in shares of bluebird bio by 2,110.3% in the 4th quarter. Meeder Asset Management Inc. now owns 641 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 612 shares in the last quarter. NuWave Investment Management LLC bought a new stake in shares of bluebird bio in the 4th quarter worth $135,000. Wealthcare Advisory Partners LLC bought a new stake in shares of bluebird bio in the first quarter worth $171,000. D.A. Davidson & CO. bought a new stake in shares of bluebird bio in the fourth quarter worth $214,000. Finally, Laurel Wealth Advisors Inc. bought a new stake in shares of bluebird bio in the first quarter worth $215,000.
About bluebird bio
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.